Primary sclerosing cholangitis
is more common in men than women. Initially, many individuals have
no symptoms and the disease is detected because of abnormal laboratory
test results, particularly an enzyme test called alkaline phosphatase.
It usually begins in the 30s, 40s, and 50s, and is commonly associated
with fatigue, itching and jaundice. Episodes of fever and chills from superimposed
infection in the bile ducts occasionally occur and can be distressing symptoms.
The diagnosis of primary sclerosing cholangitis is made by cholangiography,
an X-ray test involving injection of dye into the bile ducts. This is usually
accomplished by an endoscopic procedure called ERCP (endoscopic retrograde
cholangiopancreatography) but also may be done radiologically or surgically.
The course of the disease is unpredictable
for the patient, but is generally slowly progressive. The patient
may have the disease for many years before symptoms develop. Symptoms may
persist at a stable level, be intermittent, or progress gradually. Liver
failure may occur after 7-15 years of disease or even longer. Approximately
10% of patients who have the disease on a long-standing basis may develop
a superimposed tumor of the bile ducts called cholangiocarcinoma.
There is currently no specific
treatment for primary sclerosing cholangitis. Research is under way
to determine the effectiveness of a number of medications. The various
symptoms of primary sclerosing cholangitis often respond effectively to
medications that control itching, antibiotics when recurrent infections
occur, and vitamins to replace those that are deficient. In some instances,
endoscopic, radiologic, or surgical techniques may be employed to open
major blockages in the common bile duct and improve bile flow. When
progressive liver failure occurs in spite of these measures,liver
transplantation may be indicated. It is associated with a survival
rate of 75% or more and a good quality of life after recovery.
Back - Hepatitis
Study Center